CWEB

Why AYTU BioScience Is A Strong Buy - CWEB.com AYTU BioScience, Inc. ( OTCQX:AYTU ), a specialty life sciences company focused on global commercialization of novel products in the field of urology. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of m...

Spotify IPO Goes To Wall Street - CWEB.com Spotify (NYSE: SPOT ) opened for trading on the NYSE today at $165.90. With 184 million shares outstanding, this implies an approximate market value of between $37-$41 billion, far higher than its last reported valuation of $19 billion. MKM Partners has initiated the streaming-music giant at Buy and set a price target of $200 ahead of the start of NYSE trading Tuesday. RBC initiated an Outperform rating and $220 price target. The new price target adds another data point to what could be volatile trading, as Spotify's (NYSE: SPOT )  doing a rare direct listing rather than a bank-led IPO that would feature an opening pricing. Pandora is still the market leader in the U.S. for ad music streaming and still has more combined users in North America than any other music streaming app. Pandora's competitor, Spotify (NYSE: SPOT ) , is growing revenues at a faster rate but its operating expenses are also gro...

Mark Zuckerberg Hits Back At Tim Cook – CWEB.com Facebook CEO Mark Zuckerberg rejected Apple CEO Tim Cook’s critique of his company’s business model. It’s ‘extremely glib and not aligned with the truth. “You know, I find that argument, that if you’re not paying that somehow we can’t care about you, to be extremely glib,” Mr Zuckerberg sais on interview published by  Vox  today. “And not at all aligned with the truth.” He took a swipe at Apple’s notoriously expensive products, adding that Facebook was “squarely in the camp of the companies that work hard to charge you less and provide a free service that everyone can use” and “if you want to build a service which is not just serving rich people, then you need to have something that people can afford.” Tim Cook the Apple CEO last week went against the social media giant for selling people’s data to third parties, amid growing controversy over how Facebook operates. Zuckerberg said that Cook’s opinion — that Appl...

Nike A Good Buy Or Goodbye - CWEB.com Nike ( NKE ) reported strong third quarter numbers after the bell on Thursday.  However, growth prospects are relatively limited, with material margin enhancement unlikely due to the already expensive pricing of the company’s core products. The stock is overvalued at this levels and with the current trade war with China  Nike ( NKE )  will take a big hit. So Nike has demonstrated some excellent growth over the past several years, though that growth has become choppy recently. Investors would be wise to avoid the name until the price comes down because the market is assuming a high perpetual growth rate. Revenue up 3% on a currency-neutral basis. Gross margins declined 70 basis points. SG&A increased 11% led by a 15% surge in demand creation expenses. Income before taxes plunged 12% to only $1.2 billion. Nike actually needs China to hide slumping North America results.  However, in Nor...

Walmart Said To Be In Talks With Humana To Provide Health Care - CWEB.com Walmart (NYSE: WMT ) in early talks to buy health insurer Humana (NYSE: HUM ) as retailers are increasingly moving into the health care space. Those on Medicare with Humana insurance Walmart wants to partner with even considering purchase. Walmart  may be looking to dive deeper into the rapidly evolving health care market by acquiring the insurer Humana (NYSE: HUM ) , according to reports. Health-care spending accounted for about 18 percent of the U.S. economy last year, and continues to surge with an aging population, pricey medications, and a complex regime of reimbursements and middlemen. Walmart (NYSE: WMT ) and Humana  (NYSE: HUM ) already work together on prescription drug plans for individuals in the U.S. Medicare program. The plans offer some prescriptions for as little as $1, as long as customers pick up their drugs at a Walmart or Sa...

General Mills Is Raising $1 Billion For Blue Buffalo Purchase - CWEB.com General Mills (NYSE: GIS ) announces a secondary offering of about $1B worth of stock, with underwriter greenshoe of up to $100M. Proceeds will be used to help fund the Blue Buffalo Pet Products acquisition. General Mills intends to use the net proceeds from the Equity Offering, together with the net proceeds from a contemplated senior unsecured notes offering (the "Notes Offering"), the incurrence of debt under General Mills' U.S.commercial paper program and cash on hand to finance its previously announced acquisition (the "Acquisition") of Blue Buffalo Pet Products, Inc. ("Blue Buffalo") and to pay related fees and expenses.   Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as joint book-running managers and representatives of the underwriters for the Equity Offering. Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. an...

Is Micron Undervalued Or Fair Play - CWEB.com Micron Technology ( MU ) has been quite interesting trade.  “The DRAM and NAND flash memory market  growth forecasts for 2018 have been adjusted upward to 37% for DRAM (13% shown in MR18) and  17% for NAND flash (10% shown in MR18) ...The big increase in the DRAM market forecast for 2018 is primarily due to a much stronger ASP expected for this year than was originally forecast. IC Insights now forecasts that the DRAM ASP will register a 36% jump in 2018 as compared to 2017, when the DRAM ASP surged by an amazing 81%. Moreover, the NAND flash ASP is forecast to increase 10% this year, after jumping by 45% in 2017. In contrast to strong DRAM and NAND flash ASP increases, 2018-unit volume growth for these product segments is expected to be up only 1% and 6%, respectively.” --  IC Insights . Micron's common stock is cheaper than those of its suppliers and partners. The company is headed towards a 60% net profit ma...